{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:56:49Z","timestamp":1775217409402,"version":"3.50.1"},"reference-count":149,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"U.S. DoD CDMRP","award":["W81XWH-18-1-0188"],"award-info":[{"award-number":["W81XWH-18-1-0188"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine"],"published-print":{"date-parts":[[2026,4,18]]},"DOI":"10.1080\/17435889.2026.2645393","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:27:25Z","timestamp":1773851245000},"page":"1179-1193","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Applying multimodal dendrimers for prostate cancer theranostics"],"prefix":"10.1080","volume":"21","author":[{"given":"Wojciech G.","family":"Lesniak","sequence":"first","affiliation":[{"name":"UT Southwestern Medical Center","place":["Dallas, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[{"name":"UT Southwestern Medical Center","place":["Dallas, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70028"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.7759"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000117"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.4350"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-025-00927-4"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-025-00786-9"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-2665-8087"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.269996"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172807"},{"issue":"7","key":"e_1_3_4_12_1","first-page":"995","article-title":"Treatment response evaluation in prostate cancer using PSMA PET\/CT","volume":"66","author":"Gafita A","year":"2025","unstructured":"Gafita A, Schroeder JA, Ceci F, et al. Treatment response evaluation in prostate cancer using PSMA PET\/CT. J Nucl Med. 2025;66(7):995\u20131004.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.32604\/cju.2025.066700"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40336-025-00716-w"},{"key":"e_1_3_4_15_1","first-page":"101031","article-title":"Comment on \u201cPSMA response evaluation in follow-up PSMA-PET\/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer\u201d","volume":"55","author":"Aphale P","year":"2025","unstructured":"Aphale P, Shekhar H, Dokania S. Comment on \u201cPSMA response evaluation in follow-up PSMA-PET\/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer\u201d. Clin Transl Radiat Oncol. 2025;55:101031.","journal-title":"Clin Transl Radiat Oncol"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.12.025"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-005-0544-5"},{"issue":"3","key":"e_1_3_4_19_1","first-page":"217","article-title":"Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy","volume":"4","author":"Gong MC","year":"2000","unstructured":"Gong MC, Chang SS, Watt F, et al. Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. Mol Urology. 2000;4(3):217\u2013222.","journal-title":"Mol Urology"},{"issue":"1","key":"e_1_3_4_20_1","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver DA","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81\u201385.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-022-01766-y"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.010"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.03.030"},{"issue":"3","key":"e_1_3_4_24_1","first-page":"241","article-title":"Prostate-specific membrane antigen as a target for cancer imaging and therapy","volume":"59","author":"Kiess AP","year":"2015","unstructured":"Kiess AP, Banerjee SR, Mease RC, et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imag. 2015;59(3):241\u2013268.","journal-title":"Q J Nucl Med Mol Imag"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2016.26"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1583168"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-025-01686-y"},{"key":"e_1_3_4_28_1","first-page":"26","article-title":"Elucidation of the mechanisms of action of 177Lu-and 212Pb-based psma radioligand therapies","volume":"55","author":"Boucher D","year":"2025","unstructured":"Boucher D, Monterosso ME, Shakti S, et al. Elucidation of the mechanisms of action of 177Lu-and 212Pb-based psma radioligand therapies. Intern Med J. 2025;55:26\u201327.","journal-title":"Intern Med J"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07492-9"},{"key":"e_1_3_4_30_1","volume-title":"225Ac-PSMA-617 augmentation after inadequate response to 177Lu-PSMA-617 radioligand therapy in mCRPC. Evaluation of outcome and safety from a prospective registry (REALITY study)","author":"H\u00f6ffken K","year":"2025","unstructured":"H\u00f6ffken K. 225Ac-PSMA-617 augmentation after inadequate response to 177Lu-PSMA-617 radioligand therapy in mCRPC. Evaluation of outcome and safety from a prospective registry (REALITY study). Onkologie; 2025."},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40336-025-00715-x"},{"key":"e_1_3_4_32_1","first-page":"42","article-title":"Predictive and prognostic 68ga-psma pet biomarkers for 177lu-psma radioligand therapy in metastatic castrate-resistant prostate cancer (Asian population study)","volume":"55","author":"Koh N","year":"2025","unstructured":"Koh N, Chua WM, Lam W, et al. Predictive and prognostic 68ga-psma pet biomarkers for 177lu-psma radioligand therapy in metastatic castrate-resistant prostate cancer (Asian population study). Intern Med J. 2025;55:42\u201342.","journal-title":"Intern Med J"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-025-00946-w"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23765"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23922"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2548"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2019.02.008"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41824-018-0044-0"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-6736"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107803"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2752"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-3997"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0927"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2776"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-2638"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1543"},{"issue":"5","key":"e_1_3_4_47_1","first-page":"927","article-title":"Monoclonal-antibodies to a New antigenic Marker in epithelial prostatic cells and serum of prostatic-cancer patients","volume":"7","author":"Horoszewicz JS","year":"1987","unstructured":"Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal-antibodies to a New antigenic Marker in epithelial prostatic cells and serum of prostatic-cancer patients. Anticancer Res. 1987;7(5):927\u2013936.","journal-title":"Anticancer Res"},{"key":"e_1_3_4_48_1","first-page":"S364","article-title":"(111)Indium Capromab Pendetide (CP) imaging (PROSTASCINT (R)) in the management of recurrent prostate carcinoma (CaP): one centers experience","volume":"38","author":"Lamonica D","year":"2011","unstructured":"Lamonica D, Rivero-Martino W, Tan Z, et al. (111)Indium Capromab Pendetide (CP) imaging (PROSTASCINT (R)) in the management of recurrent prostate carcinoma (CaP): one centers experience. Eur J Nucl Med Mol Imag. 2011;38:S364\u2013S364.","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.8.2.175"},{"issue":"17","key":"e_1_3_4_50_1","first-page":"3629","article-title":"Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium","volume":"57","author":"Liu H","year":"1997","unstructured":"Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57(17):3629\u20133634.","journal-title":"Cancer Res"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000091655.77601.0c"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.160"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0231"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.154"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000625"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01963-7"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0708"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.90140.4592"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0532"},{"issue":"18","key":"e_1_3_4_60_1","first-page":"217s","article-title":"Phase I\/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC)","volume":"24","author":"Milowsky MI","year":"2006","unstructured":"Milowsky MI, Galsky M, George DJ, et al. Phase I\/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC). J Clin Oncol. 2006;24(18):217s\u2013217s.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2011-3668"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.4662"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.4650"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-353"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-3145"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-CT121"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm950801q"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.2.749"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm000406m"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-025-01268-2"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2015.09.011"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2021.03.008"},{"key":"e_1_3_4_73_1","first-page":"1850","article-title":"Meeting ReportOCTD: genitourinary beyond vision: superior outcomes and personalized care in mCRPC with Pluvicto","volume":"66","author":"Kulkarni H","year":"2025","unstructured":"Kulkarni H, Maupin K, Van Oss J, et al. Meeting ReportOCTD: genitourinary beyond vision: superior outcomes and personalized care in mCRPC with Pluvicto. J Nucl Med. 2025;66:1850.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_74_1","first-page":"251559","article-title":"Overall survival of prostate cancer patients treated with Lu-177 PSMA 617 (Pluvicto\u00ae) in a multidisciplinary setting-a single center experience","volume":"66","author":"Prasad V","year":"2025","unstructured":"Prasad V, Pachynski R, Gay H, et al. Overall survival of prostate cancer patients treated with Lu-177 PSMA 617 (Pluvicto\u00ae) in a multidisciplinary setting-a single center experience. J Nucl Med. 2025;66:251559\u2013251559.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_75_1","first-page":"1280","article-title":"Radioligand therapy with Lu-PSMA-617 in patients with diffuse bone marrow involvement: safety and efficacy","volume":"61","author":"Groner D","year":"2020","unstructured":"Groner D, Ngoc CN, Davis K, et al. Radioligand therapy with Lu-PSMA-617 in patients with diffuse bone marrow involvement: safety and efficacy. J Nucl Med. 2020;61:1280\u20131280.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003651"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2014-CT210"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(14)70167-4"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biomac.6b01485"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2006.10.125"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST0350061"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.progpolymsci.2013.07.005"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1080\/00914037.2022.2158334"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpolymj.2021.110683"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1186\/1556-276X-9-247"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2021.659304"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25153333"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1871"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104589"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-12-814527-2.00004-4"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1021\/bm101046d"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom9090421"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2015.03.019"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-814527-2.00011-1"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.2174\/1567201818666211021160441"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1080\/10837450.2023.2173230"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2016.07.015"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.4103\/0975-7406.130965"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.3390\/ma13010065"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2014.02.021"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2017.07.051"},{"key":"e_1_3_4_102_1","article-title":"Acetylated and phosphoryl cholinated G5 poly(amidoamine) dendrimers for gene delivery: balancing toxicity and DNA packaging efficiency","volume":"255","author":"Wieser T","year":"2018","unstructured":"Wieser T, Prevette L. Acetylated and phosphoryl cholinated G5 poly(amidoamine) dendrimers for gene delivery: balancing toxicity and DNA packaging efficiency. Abstr Papers Am Chem Soc. 2018;255. https:\/\/www.morressier.com\/o\/event\/5fc63fa103137aa5257ba0c8\/article\/5fc640832d78d1fec4649059","journal-title":"Abstr Papers Am Chem Soc"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.3390\/macromol3020022"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.a.34359"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1039\/C5SM01153A"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.05.049"},{"key":"e_1_3_4_107_1","article-title":"Small molecule encapsulation in PAMAM dendrimers","volume":"245","author":"Jolly A","year":"2013","unstructured":"Jolly A, Bonizzoni M. Small molecule encapsulation in PAMAM dendrimers. Abstr Papers Am Chem Soc. 2013;245:1155.","journal-title":"Abstr Papers Am Chem Soc"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10856-013-4969-3"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1021\/nl051077u"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1557\/PROC-845-AA5.37"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1080\/17435390902725922"},{"key":"e_1_3_4_112_1","first-page":"65","article-title":"Metal\/Dendrimer nanocomposites for enhanced optical breakdown: acoustic characterization and initial targeted cell uptake study","volume":"6449","author":"Tse C","year":"2007","unstructured":"Tse C, Lesniak W, Balogh LP, et al. Metal\/Dendrimer nanocomposites for enhanced optical breakdown: acoustic characterization and initial targeted cell uptake study. Genetically Engineered Optical Probes Biomed Appl Iv. 2007;6449:65\u201374.","journal-title":"Genetically Engineered Optical Probes Biomed Appl Iv"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp7001208"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.2217\/nnm.11.67"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-1716"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-020-01631-8"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-23-C167"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3014"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-23-B039"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3004"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0863"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179168"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1021\/bm049704h"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1021\/bc0499127"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1021\/bm401777w"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2019.110762"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fbio.2023.103200"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-018-3352-6"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1021\/bm301719b"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28176334"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10030162"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp3005325"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.9b00181"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1039\/D1NR00669J"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0018"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S454128"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1039\/D3NR06520K"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biomac.4c00878"},{"issue":"14","key":"e_1_3_4_139_1","first-page":"4029","article-title":"Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen","volume":"62","author":"Lupold SE","year":"2002","unstructured":"Lupold SE, Hicke BJ, Lin Y, et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 2002;62(14):4029\u20134033.","journal-title":"Cancer Res"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27113446"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S282107"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-021-00358-0"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02972-w"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.1021\/bm201639c"},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1039258"},{"key":"e_1_3_4_146_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.7b11024"},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-025-01014-w"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.11.015"},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2010.04.009"},{"key":"e_1_3_4_150_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2010.139"},{"key":"e_1_3_4_151_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3330"}],"container-title":["Nanomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17435889.2026.2645393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:08:24Z","timestamp":1775214504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17435889.2026.2645393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":149,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,4,18]]}},"alternative-id":["10.1080\/17435889.2026.2645393"],"URL":"https:\/\/doi.org\/10.1080\/17435889.2026.2645393","relation":{},"ISSN":["1743-5889","1748-6963"],"issn-type":[{"value":"1743-5889","type":"print"},{"value":"1748-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=innm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=innm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}